《改善全球肾脏病预后组织2020年临床实践指南:慢性肾脏病患者的糖尿病管理》推荐的降血糖治疗方案解读  

Antihyperglycemic therapies in patients with type 2 diabetes and chronic kidney disease from KDIGO 2020 clinical practice guideline

作　　者：仙淑丽[1] 丁峰[1] 李雪竹 XIAN Shuli;DING Feng;LI Xuezhu(Division of Nephrology,Shanghai Ninth People’s Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200011,China)

机构地区：[1]上海交通大学医学院附属第九人民医院肾内科,上海200011

出　　处：《上海医药》2022年第3期8-11,共4页Shanghai Medical & Pharmaceutical Journal

摘　　要：改善全球肾脏病预后组织(Kidney Disease:Improving Global Outcomes,KDIGO)发布了《KDIGO 2020年临床实践指南:慢性肾脏病患者的糖尿病管理》。该指南总结了以往的临床循证医学证据,尤其是近年来新型降血糖药物治疗对糖尿病患者靶器官保护的高质量证据,从血糖水平控制、生活方式干预和降血糖药物的选择等方面给出了临床医师科学管理糖尿病合并慢性肾脏病患者的推荐或建议。In 2020,the Kidney Disease:Improving Global Outcomes(KDIGO)first launched the clinical practice guideline related to diabetes management in chronic kidney disease.This guideline summarizes the evidences of the past clinical evidence-based medicine,especially the high-quality evidences on the protection of targeted organs with new antihyperglycemic agents in recent years,and gives clinicians recommendations or suggestion for systemic managements of patients with diabetes and chronic kidney disease in terms of blood glucose level control,lifestyle interventions and choice of antihyperglycemic drugs.

关 键 词：糖尿病 慢性肾脏病 降血糖治疗 

分 类 号：R587.2[医药卫生—内分泌] R969.3[医药卫生—内科学]